Antibiotic monensin synergizes with EGFR inhibitors and oxaliplatin to suppress the proliferation of human ovarian cancer cells
Citations Over TimeTop 10% of 2015 papers
Abstract
Ovarian cancer is the most lethal gynecologic malignancy with an overall cure rate of merely 30%. Most patients experience recurrence within 12-24 months of cure and die of progressively chemotherapy-resistant disease. Thus, more effective anti-ovarian cancer therapies are needed. Here, we investigate the possibility of repurposing antibiotic monensin as an anti-ovarian cancer agent. We demonstrate that monensin effectively inhibits cell proliferation, migration and cell cycle progression, and induces apoptosis of human ovarian cancer cells. Monensin suppresses multiple cancer-related pathways including Elk1/SRF, AP1, NFκB and STAT, and reduces EGFR expression in ovarian cancer cells. Monensin acts synergistically with EGFR inhibitors and oxaliplatin to inhibit cell proliferation and induce apoptosis of ovarian cancer cells. Xenograft studies confirm that monensin effectively inhibits tumor growth by suppressing cell proliferation through targeting EGFR signaling. Our results suggest monensin may be repurposed as an anti-ovarian cancer agent although further preclinical and clinical studies are needed.
Related Papers
- → Biochemical Studies on the Fate of Monensin in Animals and in the Environment(1984)211 cited
- → Anti-methanogenic effects of monensin in dairy and beef cattle: A meta-analysis(2013)166 cited
- → Effect of Monensin on Growth, Feed Efficiency and Energy Metabolism of Lambs(1979)65 cited
- Oocyst discharge, rumen metabolism and performance of early weaned lambs with naturally occurring coccidiosis fed monensin.(1981)
- Monensin의 급여가 한우의 증체 및 제1위액의 성상에 미치는 영향(2000)